Millie
your market intelligence analyst
Search Results
18 results
Your search is now limited to «AstraZeneca» expert search.
Your search is now limited to only one Source. To return to results from all sources click here.
ENDPOINTS 09/23/2019 10:05
→ UK-based early cancer detection company Oncimmune Holdings Tariq Sethi as CSO, Matthew Luttrell as CMO and Cléa Rosenfeld as head of investor relations. Sethi is a professor of respiratory medicine at King’s College London. Before jumping on board at Oncimmune, Sethi was chief physician-scientist, vice president in the clinical discovery unit at AstraZeneca . He is also the founder of Galecto Biotech . Luttrell joins the company after a stint as head of hematology, growth and emerging markets at Shire (now Takeda ). He’s served in other roles at Eli Lilly , Novo Nordisk , Gilead , and GSK . Rosenfeld brings experience to her new role from her time as head of investor relations at Shire, where she helped bring the company from a FTSE 250 C.
ENDPOINTS 08/21/2019 04:02
AstraZeneca bet big on the future of their PD-L1 Imfinzi combined with the experimental CTLA-4 drug tremelimumab. But once again it’s gone down to defeat in a major Phase III study — while adding damage to the theory involving targeting cancer with a high tumor mutational burden. Early Wednesday the pharma giant announced that their NEPTUNE study had failed, with the combination unable to beat standard chemo at overall survival in high TMB cases of advanced non-small cell lung cancer. We won’t get hard data until later in the year, but the drumbeat of failures will call into question what — if any — future this combination can have left.
ENDPOINTS 08/07/2019 07:28
For men with metastatic castration-resistant prostate cancer the disease remains deadly, especially in those who have failed on a new hormonal anticancer treatment,” José Baselga, AstraZeneca’s head of oncology R&D. The 340 patients recruited in the PROfound study are all confirmed, via genomic testing to harbor mutations in one of 15 homologous recombination repair genes.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications